|
Major Depressive Disorder
|
0.500 |
Biomarker
|
disease |
CTD_human |
Alterations in the neuropeptide galanin system in major depressive disorder involve levels of transcripts, methylation, and peptide.
|
27940914 |
2016 |
|
Major Depressive Disorder
|
0.500 |
Biomarker
|
disease |
PSYGENET |
These results may contribute to the understanding of the pathophysiology of major depressive disorder and the role of GalR2 in the regulation of mood, and suggest a potential therapeutic effect by targeting the GalR2 for treatment of depressive disorders.
|
21672612 |
2011 |
|
Depressive disorder
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
Here we report that variants in genes for galanin (GAL) and its receptors (GALR1, GALR2, GALR3), despite their disparate genomic loci, conferred increased risk of depression and anxiety in people who experienced childhood adversity or recent negative life events in a European white population cohort totaling 2,361 from Manchester, United Kingdom and Budapest, Hungary.
|
24706871 |
2014 |
|
Depressive disorder
|
0.320 |
Biomarker
|
disease |
PSYGENET |
These results may contribute to the understanding of the pathophysiology of major depressive disorder and the role of GalR2 in the regulation of mood, and suggest a potential therapeutic effect by targeting the GalR2 for treatment of depressive disorders.
|
21672612 |
2011 |
|
Depressive disorder
|
0.320 |
Biomarker
|
disease |
BEFREE |
Phenotypic analysis of GalR2 knockout mice in anxiety- and depression-related behavioral tests.
|
18554714 |
2008 |
|
Depressive disorder
|
0.320 |
Biomarker
|
disease |
PSYGENET |
Phenotypic analysis of GalR2 knockout mice in anxiety- and depression-related behavioral tests.
|
18554714 |
2008 |
|
Alcoholic Intoxication, Chronic
|
0.310 |
Biomarker
|
disease |
BEFREE |
There was no effect of GALR1 or GALR2 on alcoholism risk.
|
17083333 |
2007 |
|
Involutional Depression
|
0.300 |
Biomarker
|
disease |
CTD_human |
Alterations in the neuropeptide galanin system in major depressive disorder involve levels of transcripts, methylation, and peptide.
|
27940914 |
2016 |
|
Involutional paraphrenia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Alterations in the neuropeptide galanin system in major depressive disorder involve levels of transcripts, methylation, and peptide.
|
27940914 |
2016 |
|
Psychosis, Involutional
|
0.300 |
Biomarker
|
disease |
CTD_human |
Alterations in the neuropeptide galanin system in major depressive disorder involve levels of transcripts, methylation, and peptide.
|
27940914 |
2016 |
|
Unipolar Depression
|
0.300 |
Biomarker
|
disease |
PSYGENET |
These results may contribute to the understanding of the pathophysiology of major depressive disorder and the role of GalR2 in the regulation of mood, and suggest a potential therapeutic effect by targeting the GalR2 for treatment of depressive disorders.
|
21672612 |
2011 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Additionally, galanin had no effect on the hemoglobin content of tumors derived from cells lacking GALR2.
|
29123986 |
2017 |
|
Neoplasms
|
0.080 |
PosttranslationalModification
|
group |
BEFREE |
To determine the prognostic value of GAL, GALR1 and GALR2 methylation status, their associations with various clinical characteristics and patient survival were assessed in HNSCC patient tumors (n = 142).
|
26572146 |
2016 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
SSTR1 hypermethylation in 64% of cases was correlated with tumor size (P = 0.037), stage (P = 0.037), SST methylation (P < 0.001), and expression of galanin (P = 0.03), GALR2 (P = 0.014), TAC1 (P = 0.023), and tachykinin receptor type 1 (TACR1) (P = 0.003).
|
25734919 |
2015 |
|
Neoplasms
|
0.080 |
PosttranslationalModification
|
group |
BEFREE |
GALR2 methylation found in 31 of 100 (31.0%) tumor specimens was significantly correlated with the methylation status of both GALR1 and Galanin.
|
24122450 |
2014 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
In the present study, it was demonstrated that the re‑expression of GALR1 in GALR1 and GALR2‑negative HNSCC cells suppresses tumor cell proliferation.
|
25017118 |
2014 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Expression of GalR1 was relatively increased in most, whereas GalR2 was decreased in some tumors.
|
22889491 |
2012 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
In head and neck squamous carcinoma cells (HNSCC) with silenced GALR1 and GALR2, we showed that reexpressed GALR1 suppresses tumor cell proliferation via Erk1/2-mediated effects on cdk inhibitors and cyclin D1.
|
19276245 |
2009 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Pharmacological analysis of tumor membrane homogenates with GAL and the specific GAL receptor GalR2 agonist, AR-M1896, revealed that the GAL receptor GalR1 is most likely the receptor responsible for the observed GAL binding in the glioblastomas.
|
12734662 |
2003 |
|
Squamous cell carcinoma of the head and neck
|
0.050 |
PosttranslationalModification
|
disease |
BEFREE |
To determine the prognostic value of GAL, GALR1 and GALR2 methylation status, their associations with various clinical characteristics and patient survival were assessed in HNSCC patient tumors (n = 142).
|
26572146 |
2016 |
|
Squamous cell carcinoma of the head and neck
|
0.050 |
Biomarker
|
disease |
BEFREE |
SST methylation in 81% of HNSCC tumor specimens significantly correlated with tumor size (P = 0.043), stage (P = 0.008), galanin receptor type 2 (GALR2) methylation (P = 0.041), and tachykinin-1 (TAC1) (P = 0.040).
|
25734919 |
2015 |
|
Squamous cell carcinoma of the head and neck
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
The impact of GALR2 expression on secretion of proangiogenic cytokines in multiple SCCHN cell lines was investigated by ELISA and in vitro angiogenesis assays.
|
24568968 |
2014 |
|
Squamous cell carcinoma of the head and neck
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, GALR2 expression in the presence of galanin exerts antitumor effects via cell cycle arrest and apoptotic pathways, and reactivation of these pathways may have therapeutic benefits in HNSCC.
|
25017118 |
2014 |
|
Squamous cell carcinoma of the head and neck
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
These results illustrate that transient GALR2 expression in the presence of galanin induces apoptosis via diverse pathways and serves as a platform for suicide gene therapy against HNSCC.
|
24168112 |
2014 |
|
Anxiety
|
0.040 |
Biomarker
|
disease |
BEFREE |
These results indicate that GALR2/NPYY1R interactions in medial paracapsular intercalated amygdala can provide a novel integrative mechanism in anxiolytic behavior and the basis for the development of heterobivalent agonist drugs targeting GALR2/NPYY1R heteromers, especially in the ITCp-dl of the amygdala for the treatment of anxiety.
|
29765307 |
2018 |